MAM
Prince Pipes Ropes In Akshay Kumar as brand ambassador
NEW DELHI: Prince Pipes and Fittings Ltd (PPFL), one of India’s largest integrated piping solutions and multi polymer manufacturers, today announced that actor Akshay Kumar will represent the company as brand ambassador for its recently launched water tanks segment. In present times, when health is of primary concern, the association will provide even more impetus to the company’s vision by capitalising on Akshay’s tremendous brand recall to reinforce the brand values of Prince Pipes centering on trust, quality and high value. The actor will also continue to be the brand ambassador for the company’s piping business.
Prince Pipes is one of the leading polymer pipes and fittings manufacturers in India in terms of production capacity, number of distributors, and number and variety of products manufactured. The company’s product portfolio comprises an array of piping solutions used for varied applications in plumbing, irrigation, and sewage disposal and a range of 7167 SKUs, and now also includes the newly launched water tanks category.
Akshay Kumar said, “Enduring relationships must be cherished and valued. I am very happy to be associating with Prince Pipes once again and to continue the work we have done so far for a very important cause. This association reflects our common belief in trust, quality and value and I surely look forward to the journey ahead.”
Prince Pipes and Fittings executive director Parag Chheda said, “Akshay has been the brand ambassador for Prince Pipes since 2018 and we are delighted to extend this association with him and work with him for the new water tank segment, which is expected to grow at a high pace. He has been an integral influencer of several Indian social issues and the Prince Pipes brand portfolio resonates very well with Akshay’s ability to reach out to our industry participants across India, especially in Tier 2/3 regions and hyper local domains. With a 30 year legacy in manufacturing high quality water piping and now storage systems for a whole gamut of applications, our brand stands for expertise, trust, quality and high value, which are also true to Akshay.”
Follow Tellychakkar for the consumer facing news & entertainment
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
